
|Videos|May 5, 2017
Immunotherapy Combinations on the Horizon in Melanoma
Author(s)Jason J. Luke, MD
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses immunotherapy combinations on the horizon in melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC
5


































